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ammonia uptake matched with FDG may have been called “scar.”
In some patients, this approach could underestimate viable myo-
cardium defined by FDG imaging and bias against directing
patients to surgery after FDG PET.
Sample size (n 5 103). A 20% overall event rate was proposed
based on a previous study (11). The selection of 20% difference
(presumably SPECT 30% and PET 10%) appears arbitrary. This
would represent an overly optimistic 66% relative reduction in
event rate for this relatively low-risk patient population. Smaller
differences would still be clinically relevant particularly for patients
with severe LV dysfunction. At least one ongoing randomized
controlled study will recruit 412 patients with severe LV dysfunc-
tion to show a 30% relative reduction in event rate, based on
previous outcome studies in a similar population (2); the impact of
FDG PET-guided therapy (9) on outcomes and costs will be
compared to standard care in this study.
In summary, the interpretation of the results of the study by
Siebelink et al. (1) is hindered by the limitations common to many
clinical trials, namely those of appropriate patient selection and
sample size. Therefore, it is difficult to draw conclusions regarding
the role of either technique in the most appropriate group of
patients for viability testing—those with severe LV dysfunction.
The study, however, does provoke the need for larger randomized
controlled trials evaluating this problem, some of which are under
way. The researchers should be congratulated on being the first to
take this initiative.
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REPLY
Beanlands and colleagues make some interesting remarks on which
we would like to comment.
The purpose of our study was to evaluate in a prospective,
blinded, and randomized clinical setting what effect positron
emission tomography (PET) and single-photon emission com-
puted tomographic (SPECT) imaging had on patient management
(revascularization or drug treatment) and clinical outcome (cardiac
events) in patients in whom jeopardized myocardium was sus-
pected (1). Therefore, the population in our study resembles the
everyday clinical practice of 103 patients who are candidates for
viability testing. In our population the event rate was 23%, and
there was no significant difference in patient management and
clinical outcome between PET and SPECT-based patient man-
agement. As Beanlands and colleagues state, the clinical relevance
of observed differences often remains arbitrary and may vary with
different patient populations (e.g., severe left ventricular [LV]
dysfunction). However, we believe that in our study the observed
differences in cardiac event rate were not clinically meaningful,
because 19,250 patients should have been included to reach a
significant p value.
Concerning the patient population in our study, we are well
aware of the fact that most patients (65%) had mild to moderate
LV dysfunction. Therefore, conclusions on patients with severe
LV dysfunction should be interpreted with caution, although our
prospective, blinded and randomized study indicates that clinical
outcome might not be different between PET and SPECT-based
management in this category.
At the time we designed the study we used the most appropriate
criteria for the detection of jeopardized myocardium (1). Obvi-
ously, during the study we were not able to incorporate new
insights concerning detection of jeopardized myocardium. If more
patients with severe LV dysfunction were included in our study we
can only speculate whether this would have led to increased
discrepancies between PET and SPECT. It also remains specula-
tive whether these discrepancies would have resulted in different
management and different clinical outcome.
Opposite to what Beanlands and colleagues suggest, we believe
that our study contains no selection bias toward revascularization,
but just addresses the practical clinical question: revascularize or
not, depending on the amount of jeopardized myocardium. The
intended revascularization in our study was planned with an
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urgency-based schedule. We agree with Beanlands and colleagues
that this could reduce some of the benefits of revascularization
when revascularization is delayed (2), but the urgency-based
schedule illustrates the clinical reality in an HMO-oriented health
care system.
We fully agree with Beanlands and colleagues that larger
randomized, controlled clinical trials are needed, and we are
pleased to hear that some are underway. In our opinion these
studies should address the role of various viability techniques
(PET, SPECT, echocardiography, magnetic resonance imaging)
in different patient populations (mild, moderate, severe LV dys-
function) and their cost-effectiveness. Preferably, these studies
should be conducted in a blinded fashion to prevent selection
biases, as we have demonstrated (1). Moreover, we believe these
studies should focus on patient management and clinical outcome,
because that is what is most important to patients in the everyday
clinical practice (3).
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Periodontal Disease and
Risk of Myocardial Infarction
As interesting and impressive as “Periodontal Disease and Risk of
Subsequent Cardiovascular Disease in U.S. Male Physicians” (1)
may be with its study of 22,037 participants, its conclusions are
likely to mislead readers and block further essential research on
that relationship. The conclusion, excluding a relationship, is in
direct conflict with the report of Deliargyris et al. (2) presented at
the annual meeting of the American Heart Association last
November as well as with my own report in Dentistry Today (3).
These latter two reports, contrariwise, “indicate that acute myo-
cardial infarction (AMI) patients are more likely to have periodon-
tal disease than a comparable control population without coronary
artery disease.”
Hardly recognized by the patient but easily identified by the
periodontist, gingivitis with .4-mm pockets (the criteria of
Deliargyris et al. (2) for periodontal disease predictive of acute
myocardial infarction) would have been largely overlooked by the
Howell et al. group (1). It seems almost certain, therefore, that the
Howell et al. (1) group of self-reported periodontal disease fails to
include many, if not most, cases with gingivitis with .4-mm
pockets, which the Deliargyris et al. (2) group found to be
predictive of AMI. This makes the sample unreliable for statistical
decision making; but even excluding this error, the Howell et al.
(1) group reported a “small (10% to 20%), and statistically
nonsignificant increased risk for nonfatal myocardial infarction,
nonfatal stroke and cardiovascular death” among the group that
self-reported periodontal disease.
Although controversy on this matter continues, further investi-
gation remains appropriate. During this time, the patient’s health
is likely to benefit; and both physicians and dentists are likely to
benefit, professionally, with continued cooperation in further
studies.
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REPLY
Dr. Wehrmacher expresses concern that reliance on participant
self-reports of periodontal disease in our analysis of periodontal
disease and subsequent cardiovascular disease in the Physicians’
Health Study (1) probably resulted in the failure to include some
cases of periodontal disease. We agree that some cases of peri-
odontal disease may have been missed. However, as discussed in
the study, the magnitude of any such misclassification (which is
likely to have been random with respect to subsequent cardiovas-
cular disease) is unlikely to have caused us to miss a two- to
threefold increased risk of cardiovascular disease reported in earlier
studies. Furthermore, as also discussed in the study, associations
were noted between reported periodontal disease and age and
cigarette smoking, two acknowledged risk factors for periodontal
disease, providing support for the validity of this measure in our
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